“Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials”, J of Skin, vol. 9, no. 6, p. s669, Nov. 2025, doi: 10.25251/2vrcdb23.